As of May 27, 2025, BioInvent International AB has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $37.10, this represents a potential upside of -1919125177268.4%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -97937982.5% |
| Potential Upside (10-year) | -1919125177268.4% |
| Discount Rate (WACC) | 5.4% - 8.1% |
Revenue is projected to grow from $45 million in 12-2024 to $635312102462 million by 12-2034, representing a compound annual growth rate of approximately 935.1%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 45 | 37% |
| 12-2025 | 1231 | 2655% |
| 12-2026 | 16595 | 1248% |
| 12-2027 | 222911 | 1243% |
| 12-2028 | 2465148 | 1006% |
| 12-2029 | 24854359 | 908% |
| 12-2030 | 227926266 | 817% |
| 12-2031 | 1897141595 | 732% |
| 12-2032 | 14414612013 | 660% |
| 12-2033 | 99978280294 | 594% |
| 12-2034 | 635312102462 | 535% |
Net profit margin is expected to improve from -961% in 12-2024 to -763% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (429) | -961% |
| 12-2025 | (9,389) | -763% |
| 12-2026 | (126,571) | -763% |
| 12-2027 | (1,700,127) | -763% |
| 12-2028 | (18,801,487) | -763% |
| 12-2029 | (189,562,217) | -763% |
| 12-2030 | (1,738,375,462) | -763% |
| 12-2031 | (14,469,347,724) | -763% |
| 12-2032 | (109,939,096,809) | -763% |
| 12-2033 | (762,526,374,355) | -763% |
| 12-2034 | (4,845,474,763,624) | -763% |
with a 5-year average of $11 million. Projected CapEx is expected to maintain at approximately 24% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 68 |
| 12-2026 | 847 |
| 12-2027 | 11350 |
| 12-2028 | 127525 |
| 12-2029 | 1298859 |
| 12-2030 | 12040512 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 49 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2025 | (12,914) | (2,436) | 290 | 194 | (10,962) |
| 2026 | (174,163) | (32,838) | 3911 | 2520 | (147,756) |
| 2027 | (2,339,420) | (441,091) | 52527 | 32993 | (1,983,849) |
| 2028 | (25,869,343) | (4,877,968) | 580888 | 338417 | (21,910,680) |
| 2029 | (260,809,342) | (49,181,129) | 5856682 | 3549455 | (221,034,350) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -97937982.5% |
| 10-Year DCF (Growth) | 0.00 | -1919125177268.4% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is BioInvent International AB (BINV.ST) a buy or a sell? BioInvent International AB is definitely a sell. Based on our DCF analysis, BioInvent International AB (BINV.ST) appears to be overvalued with upside potential of -1919125177268.4%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $37.10.